引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 45次   下载 14 本文二维码信息
码上扫一扫!
ADAM17通过调控NOTCH1/Hes1信号通路抑制肝癌HepG2细胞生长的研究
孙传喜,郭娟,陆俊伶,张维,周晓霞
0
(广元市第一人民医院消化内科;成都医学院第一附属医院呼吸内科;成都市第二人民医院妇产科)
摘要:
【摘要】 目的 探讨ADAM17对肝癌HepG2细胞生长的调控作用及其对NOTCH1/Hes1信号通路的影响。方法 采用shRNAADAM17抑制肝癌HepG2细胞中ADAM17的表达。将细胞分为空白对照组、shRNAscrambled组(阴性对照组)和shRNAADAM17组(干预组)。使用MTT法测定在不同时间点(0、24、48h)对肝癌HepG2细胞的增殖水平。在干预4h后,使用qPCR法对HepG2细胞中ADAM17、NOTCH1和Hes1 mRNA水平进行检测,并对ADAM17、NOTCH1和Hes1蛋白水平采用western blot进行测定。结果 与对照组相比较,干预组干预的HepG2细胞活性呈时间依赖性下降,差异均有统计学意义(P<0.05),而阴性对照组干预的HepG2细胞各时间点差异均无统计学意义(P均>0.05)。在干预4h后与对照组相比较,干预组干预的HepG2细胞ADAM17、NOTCH1和Hes1 mRNA和蛋白表达水平均明显降低,差异均有统计学意义(P<0.05);同时与对照组相比较,阴性对照组干预的HepG2细胞ADAM17、NOTCH1和Hes1 mRNA和蛋白表达水平无明显统计学差异(P均>0.05)。 结论 ADAM17主要是通过NOTCH1/Hes1信号通路调控肝癌HepG2细胞的增殖,提示ADAM17可能是治疗肝细胞癌的潜在分子靶点。
关键词:  肝癌  ADAM17  NOTCH1  Hes1  HepG2细胞
DOI:
基金项目:国家自然科学基金青年科学基金
ADAM17 inhibits the proliferation of liver cancer HepG2 cells by NOTCH1/Hes1 signaling pathway
SUN Chuanxi,GUO Juan,LU Junling,ZHANG Wei,ZHOU Xiaoxia
(Gastroenterology Department, The First Hospital of Guangyuan;Respiratory Department, The First Affiliated Hospital of Chengdu Medical Collage;Obstetrics and Gynecology Department, The Second Hospital of Chengdu)
Abstract:
【Abstract】 Objective To study the role of ADAM17 in the proliferation of liver cancer HepG2 cells, and its underlying mechanism. Methods ShRNAADAM17 was used to abrogate the expression of ADAM17 in liver cancer HepG2 cells. In this study, HepG2 cells were divided into the control group, the shRNAscrambled group (negative group) and the shRNAADAM17 group. At different time points (0h, 24h, and 48h), the cell viabilities of HepG2 cells were analyzed by MTT assay. After 4h of interventions, the mRNA expression of ADAM17, NOTCH1, and Hes1 was measured by qPCR. Then, after 4h of interventions, western blot was performed to identify ADAM17, NOTCH1, and Hes1 protein expression. Results The cell viabilities of liver cancer HepG2 cells were timedependently inhibited by shRNAADAM17. However, no differences in the cell viabilities of liver cancer HepG2 cells between the control group and the shRNAscrambled group was found. The mRNA and protein expression of ADAM17, NOTCH1, and Hes1 were all reduced by shRNAADAM17 in liver cancer HepG2 cells, after 4h of interventions. There was no difference in ADAM17, NOTCH1, and Hes1 expression between the control group and shRNAscrambled group. Conclusion In the current study, our results indicate that the proliferation of liver cancer HepG2 cells could be suppressed by the downregulation of ADAM17 possibly through inhibition of NOTCH1/Hes1 signaling pathway, suggesting ADAM17 as a potential treatment target of liver cancer in future.
Key words:  Liver cancer  ADAM17  NOTCH1  Hes1  HepG2 cells

用微信扫一扫

用微信扫一扫